Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion
May 16th, 2025
1.5K views
This protocol provides a detailed, step-by-step procedure for the induction of thoracic aortic dissection in mice. Specifically, it includes the precise calculation of the required doses of β-aminopropionitrile and angiotensin II, the procedure for osmotic pump filling, and the implantation technique of the osmotic pump.
Overview
This protocol provides a detailed, step-by-step procedure for the induction of thoracic aortic dissection in mice. It includes the precise calculation of the required doses of β-aminopropionitrile and angiotensin II, as well as the implantation technique of the osmotic pump.
Key Study Components
Area of Science
- Neuroscience
- Cardiovascular research
- Animal models
Background
- Thoracic aortic dissection is a serious cardiovascular condition.
- Understanding its mechanisms can aid in developing therapeutic strategies.
- Animal models are essential for studying this condition.
- Osmotic pumps are used for precise drug delivery in research.
Purpose of Study
- To establish a reliable model for thoracic aortic dissection in mice.
- To evaluate the effects of specific pharmacological agents.
- To enhance understanding of the disease process.
Methods Used
- Calculation of drug doses for β-aminopropionitrile and angiotensin II.
- Preparation and filling of osmotic pumps.
- Implantation of osmotic pumps in mice.
- Monitoring of physiological responses post-implantation.
Main Results
- Successful induction of thoracic aortic dissection in the animal model.
- Demonstrated the efficacy of the drug delivery method.
- Provided insights into the progression of the condition.
- Established a foundation for future research on therapeutic interventions.
Conclusions
- The protocol is effective for inducing thoracic aortic dissection in mice.
- It allows for controlled studies on the disease and potential treatments.
- Future studies can build on this model to explore further therapeutic options.
Frequently Asked Questions
What is thoracic aortic dissection?
Thoracic aortic dissection is a serious condition where the inner layer of the aorta tears, leading to severe complications.
Why use mice for this study?
Mice are commonly used in research due to their genetic similarities to humans and the ability to control experimental variables.
What are osmotic pumps?
Osmotic pumps are devices that deliver drugs at a controlled rate over an extended period, allowing for precise dosing.
How are the drug doses calculated?
The doses are calculated based on the weight of the mice and the specific pharmacological effects desired.
What are the implications of this research?
This research can lead to better understanding and treatment options for thoracic aortic dissection and related cardiovascular diseases.
Executive Industry Relevance
Robust animal models of thoracic aortic dissection (TAD) are critical for de-risking early cardiovascular target hypotheses and enabling translational continuity in preclinical research. The combined oral BAPN and subcutaneous Ang II murine model offers improved reproducibility and disease relevance, supporting predictive confidence for therapeutic mechanism studies. This refined model strengthens portfolio decision-making by providing a reliable platform for mechanistic interrogation and candidate evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of TAD pathogenesis and mechanistic target validation in a disease-relevant system.
- Supports biological de-risking by replicating key features of human TAD in vivo.
- Facilitates predictive confidence for early-stage cardiovascular targets.
Screening & Assay Development
- Provides a validated in vivo platform for evaluating pharmacological interventions targeting TAD mechanisms.
- Improves assay reproducibility and standardization through consistent model induction.
- Enables quantitative assessment of aortic pathology for compound screening.
Translational & Preclinical Research
- Aligns preclinical studies with human disease features, enhancing translational biomarker development.
- Supports continuity from discovery through preclinical validation for cardiovascular candidates.
- Reduces translational risk by modeling clinically relevant disease progression.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies and candidate evaluation for TAD therapies.
- Discovery Biology: Enables hypothesis testing and mechanistic de-risking in a physiologically relevant context.
- Screening: Provides a reproducible system for quantitative evaluation of therapeutic interventions.
- Analytics: Supports measurement of aortic structural changes and disease endpoints for comparative analysis.
- Translational Research: Facilitates alignment of preclinical findings with human TAD pathology.
- Enterprise Reuse: Offers a standardized, reusable model for cross-program cardiovascular research.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in TAD research.
- Operational Value: Enhances reproducibility and standardization across studies and teams.
- Strategic Value: Informs go/no-go decisions and optimizes resource allocation in cardiovascular portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of therapeutic candidates targeting TAD.
Implementation Considerations
- Requires expertise in murine cardiovascular modeling and surgical techniques.
- Needs access to precise drug dosing and osmotic pump infrastructure.
- Demands cross-team standardization for model induction and endpoint analysis.
- Adaptation may be needed for different mouse strains or genetic backgrounds.
- Model limitations include species-specific responses and scalability to larger systems.
Biopharma FAQs
Why does null hypothesis testing matter for BAPN/Ang II TAD validation?
Null hypothesis testing ensures that observed aortic pathology is specifically attributable to the combined BAPN and Ang II intervention, strengthening target validation and reducing mechanistic ambiguity in early discovery.
How does independent variable isolation fit the TAD model pipeline?
Isolating the effects of BAPN and Ang II allows teams to dissect individual and synergistic contributions to TAD, supporting mechanistic de-risking and informing downstream candidate selection.
What do quantitative aortic measurements enable in this model?
Quantitative assessment of aortic dilation and dissection provides objective endpoints for comparing interventions, enabling reliable screening and supporting translational biomarker development.
Why are replication requirements critical for cross-functional TAD studies?
Consistent replication of TAD induction across cohorts ensures data reliability, facilitates cross-team collaboration, and underpins robust portfolio advancement decisions.
Which statistical analysis capabilities are required before TAD model implementation?
Teams must establish statistical methods for analyzing aortic pathology, group comparisons, and model success rates to ensure rigorous evaluation and reproducibility in preclinical research.
